Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Invitation to presentation of Balco’s fourth quarter report 2018

Balco’s interim report for the fourth quarter 2018 will be published at 08:00 CET on February 22, 2019. A web-cast telephone conference will be held at 09:00 CET the same day, where CEO and President Kenneth Lundahl and CFO Fredrik Hall will present the results for the fourth quarter 2018.A possibility will be given to ask questions via the webcast and follow the presentation material live. The webcast, which afterwards also will be available on demand, will be accessible at Balco’s financial website, www.balcogroup.se or via the following link http://www.financialhearings.com/event/11456.

BONESUPPORT – Publication of pre-clinical study highlighting unique bone remodeling qualities of CERAMENT® in large bone defects

Lund, Sweden, 08.00 CET, 08 February 2019 – BONESUPPORT, an emerging leader in orthobiologics for the management of bone voids, today announces the publication of ground-breaking data on bone remodeling of CERAMENT in pre-clinical model. The study ‘Establishment and effects of allograft and synthetic bone graft substitute treatment of a critical size metaphyseal bone defect model in the sheep femur’ is published in APMIS (Acta Pathologica, Microbiologica et Immunologica Scandinavica). BONESUPPORT EVP R&D, Medical & Clinical Affairs and senior author of the publication Dr Michael

Acando Year-end report 2018

Fourth quarter October 1–December 31, 2018 · Net sales totaled SEK 797 m (693) · Operating profit amounted to SEK 83 m (87) · Operating margin was 10.4% (12.5) · Profit after tax was SEK 63 m (67) · Earnings per share were SEK 0.60 (0.64)  Accumulated, January 1–December 31, 2018 · Net sales totaled SEK 2,826 m (2,444) · Operating profit amounted to SEK 264 m (243) · Profit before non-recurring items SEK 274 m, corresponding to a margin of 9.7% · Operating margin 9.4% (10.0) · Profit after tax was SEK 209 m (180) · Earnings per share were SEK 2.01 (1.

Changes in Dometic’s group management

Per-Arne Blomquist, CFO and Deputy CEO of Dometic, has decided to leave the company to focus on new and existing board assignments. Per-Arne Blomquist will be supportive in the recruitment process and remains in his position during the transition.“I have truly appreciated being part of the fantastic Dometic journey for 5 years, and I have enjoyed working with great people in creating an even stronger company. Dometic is well positioned for continued profitable growth, and I remain fully dedicated to the company over the coming months”, says Per-Arne Blomquist.“During his time as CFO of

Polygon AB (publ) - Interim report 1 January - 31 December 2018

The trend continued in the fourth quarterFOURTH QUARTER 2018 · Sales grew 18.7% to EUR 165.9 million. Adjusted organic growth remained strong at 6.4%, driven by Continental Europe reporting growth of 12.4%. Acquisitions, completed in late 2017 and early 2018, contributed EUR 17.4 million in sales, corresponding to growth of 12.5%. The stronger euro had a negative impact of 0.2%. Order intake in the quarter was up 17.0% on last year. · Adjusted EBITA amounted to EUR 10.6 million (9.5), up 11.2%. Continental Europe was up slightly compared with last year by 3.3%, while earnings in

Hansa Biopharma Year-End Report 2018

With positive clinical results from the Company’s lead clinical program, Hansa readies for transition to commercial-stage companyOctober – December 2018 in brief ›› To better reflect its evolution and long-term aspirations, Hansa Medical AB changed its name to Hansa Biopharma AB. The new name represents the next stage in the Company’s lifecycle and emphasizes Hansa’s focus on the development and commercialization of biopharmaceuticals. This refinement of Hansa’s profile is particularly salient as the Company continues the international expansion of its business and investor base. ›› In

REPORT ON THE FOURTH QUARTER 2018

FOURTH QUARTER · Net sales for the quarter were SEK 4,070 m (3,252); an increase of 25%, of which -2% was organic growth. · Operating profit (EBIT) for the quarter was SEK 328 m (191), representing a margin of 8.1% (5.9%). · Items affecting comparability totaled SEK -92 m (-119), related to restructuring charges in a group-wide initiative to optimize footprint and reduce costs. · Operating profit (EBIT) before items affecting comparability for the quarter was SEK 420 m (310), representing a margin of 10.3% (9.5%). · Cash flow for the quarter was SEK -906 m (-612). Operating

Major projects to create value for Platzer now and in the future

· Rental income increased to SEK 1,044 million (995) · Income from property management improved by 7% to SEK 522 million (486) · Profit for the period amounted to SEK 1,511 million (1,393) · Property portfolio increased in value to SEK 18,388 million (15,559) · Income from property management per share amounted to SEK 4.36 (4.06) · Earnings per share totalled SEK 12.55 (11.54) · Long-term net asset value (EPRA NAV) per share was SEK 69.54 (58.39) · The Board of Directors proposes a dividend of SEK 1.70 per share (1.50) · Average interest rate reduced to 1.71% through

Peab Year-end report January – December 2018

Improved profit and increased dividendsOctober – December 2018 · Net sales SEK 14,845 million (14,490) · Operating profit SEK 863 million (753) · Operating margin 5.8 percent (5.2) · Pre-tax profit SEK 839 million (825) · Earnings per share SEK 2.39 (2.31) · Orders received SEK 10,451 million (13,039) · Cash flow before financing SEK 949 million (1,508) January – December 2018 · Net sales SEK 52,233 million (49,981) · Operating profit SEK 2,573 million (2,418) · Operating margin 4.9 percent (4.8) · Pre-tax profit SEK 2,518 million (2,458) ·

Midsona - YEAR END REPORT 2018

Sales growth from acquisitions and priority brandsMidsona year-end result 2018 ENG October-December 2018 (fourth quarter) ·  Net sales amounted to SEK 755 million (571). ·  EBITDA amounted to SEK 59 million (59) before items affecting comparability, corresponding to a margin of 7.8 percent (10.3). ·  Profit for the period was SEK 33 million (34), corresponding to earnings per share of SEK 0.71 (0.75) before dilution and SEK 0.70 (0.74) after dilution. ·  Free cash flow amounted to SEK 44 million (49). January-

Interim Report - 9 months 1 April-31 December 2018

Third quarter (1 October-31 December 2018) · Revenue increased by 4 percent to MSEK 1,552 (1,486). · Operating profit rose by 12 percent to MSEK 85 (76), corresponding to an operating margin of 5.5 percent (5.1). · The return on working capital (P/WC) for the most recent 12-month period was 24 percent (24) and the return on equity was 18 percent (8). · Profit after financial items rose by 14 percent to MSEK 84 (74). · Net profit increased by 10 percent to MSEK 64 (58). · Earnings per share for the most recent 12-month period totalled SEK 7.65, compared with SEK 6.45 for

Outotec's Financial Statements Review January-December 2018

OUTOTEC OYJ FINANCIAL STATEMENTS REVIEW  FEBRUARY 8, 2019 AT 9:00 AM Outotec's Financial Statements Review January-December 2018 Significant improvement in performance excluding ilmenite smelter project provision "In 2018, we made significant progress in several areas. In the beginning of the year, the market for minerals and metals technologies improved, but global macroeconomic uncertainties and reduced metal prices started to affect the market sentiment, and we saw several larger investment decisions being delayed into 2019. This was demonstrated in our order intake, which

TIKOMED successfully closed fundraising of 8 Million Euros

Viken – 8th February 2019 – TIKOMED, a Swedish privately-held biopharmaceutical company today announced its successful completion of the company’s latest fundraising of 8 Million Euros to support the ongoing clinical development program for both the ILB® program and the IBSOLVMIR® program. TIKOMED is developing therapeutics for treating acute and degenerative neurological and ophthalmic diseases (ILB® program) and an infusion product for improving outcomes in cell therapies (IBSOLVMIR® program). “I’m delighted that we have successfully completed our latest fundraising, which

Metsä Tissue kehittää konseptia tulevaisuuden pehmopaperitehtaille

Metsä Groupiin kuuluva Metsä Tissue Oyj on aloittanut tehdastoimintojensa operatiivisen tarkastelun 1.2.2019. Operatiivisesta tarkastelusta vastaa tuotantojohtaja Jari Tiura. Osana operatiivista tarkastelua Metsä Tissue kehittää tulevaisuuden pehmopaperitehdaskonseptin yhdessä laite- ja automaatiojärjestelmätoimittajien kanssa. Konseptin kehityksessä käydään läpi kaikki pehmopaperitehtaan operatiiviset prosessit: raaka-aineet, tuotanto, jalostus sekä lähetys- ja varastotoiminnot. Hankkeessa selvitetään, onko uudella konseptilla mahdollista kehittää merkittävästi tuotannon ja

Outotec makes EUR 110 million provision relating to the ilmenite smelter project

OUTOTEC OYJ  STOCK EXCHANGE RELEASE  FEBRUARY 8, 2019 at 8:55 AM Outotec makes EUR 110 million provision relating to the ilmenite smelter project Outotec has made a EUR 110 million provision for possible costs relating to the ilmenite smelter project in Saudi Arabia (Stock Exchange Releases on May 31, 2012; October 26, 2018; and October 30, 2018). The currently estimated provision is based on progress made with the analysis of the furnace. The provision is booked in Outotec's fourth quarter 2018 result. The outcome of the analysis, together with other factors such as Outotec's

Metsä Tissue is Developing a Concept for the Future Tissue Mill

Metsä Tissue, part of the Metsä Group, commenced an operational review of its mill operations on 1 February 2019. Jari Tiura, SVP, Operations, is responsible for the operational review. As part of the operational review, Metsä Tissue will be developing a concept for the future tissue paper mill in cooperation with equipment and automation system suppliers. The concept’s development will include a review of all the operational processes of a tissue paper mill: raw materials, production, converting as well as dispatch and warehouse operations. The review aims to find out whether a new

SpareBank 1 SR-Bank ASA (SRBANK): Key information relating to the cash dividend

Dividend amount: 4.50 per share Declared currency: Norwegian krone Last day including right: April 24, 2019 Ex-date: April 25, 2019 Record date: April 26, 2019 Payment date: From May 3, 2019 Date of approval: April 24, 2019 This information is published in accordance with the requirements of the Continuing Obligations. Stavanger, February 8, 2019 Contact people:Stian Helgøy, Vice President Investor Relations, Tel. +47 906 52 173This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Redeye: Calliditas Therapeutics: Progress made in Q4 – focus is on execution going forward

Calliditas is progressing according to plan with the NEFIGARD Phase III study. We provide an update on recent events.  Read more and download the analysis: http://bit.ly/2SmsckD  Start following companies at Redeye to recieve the latest equity research within Life Science and Technology. This is a press release from Redeye - Research Powered Investment Banking. https://www.redeye.se/about/

SpareBank 1 SR-Bank ASA (SRBANK): Strong result with income growth and good cost control

SpareBank 1 SR-Bank achieved a pre-tax profit of NOK 2,892 million for 2018 compared with NOK 2,610 million for 2017. The result was due to higher ordinary operating income, a moderate increase in the group’s operating costs and significantly lower impairment on loans than in 2017. The return on equity after tax was 11.3% compared with 11.0% in 2017, while the common equity tier 1 capital ratio was 14.7%, compared with 15.1% as at 31 December 2017. The pre-tax profit for the quarter in isolation was NOK 676 million, compared with NOK 700 million for the corresponding period in 2017.

XVIVO Perfusion AB (publ) Report on operations 2018

THE YEAR ENDED WITH CONTINUED STRONG GROWTH AND GOOD EBITDAFOURTH QUARTER 2018 (OCT - DEC) · Total net sales in the quarter amounted to SEK 58.4 (41.6) million, corresponding to an increase of 40 percent in SEK and 33 percent in local currency. Net sales of non-durable goods* in the quarter amounted to SEK 52.3 (39.4) million, corresponding to an increase of 33 percent in SEK and 26 percent in local currency. · Warm perfusion sales of non-durable goods** showed a record growth of more than 50 percent during the quarter. Sales from warm perfusion represented 50 percent (43) of sales

Year-end report, January–December 2018

Skanska year-end report, January-December 2018 (compared to January-December 2017)Highlights according to segment reporting - Revenue amounted to SEK 170.5 billion (160.8); adjusted for currency effects revenue increased 3 percent. - Operating income amounted to SEK 4.8 billion (5.5); adjusted for currency effects operating income decreased 14 percent. - Earnings per share decreased 21 percent to SEK 9.55 (12.01). - The Board of Directors propose a dividend of SEK 6.00 (8.25) per share. - Operating cash flow from operations amounted to SEK 7.4 billion (2.9), according to IFRS.

Notice to the Annual General Meeting 2019 of Digia Plc

Digia PlcStock Exchange Release8 February 2019 at 8:01 am Notice to the Annual General Meeting 2019 of Digia Plc Notice is given to the shareholders of Digia Plc to the Annual General Meeting to be held on Friday, 15 March 2019, starting at 10.00 a.m. at the headquarters of the company, address Atomitie 2 A, 00370 Helsinki, Finland. The reception of persons who have registered for the Meeting and distribution of voting tickets will commence at 9:00 a.m. A. MATTERS ON THE AGENDA OF THE ANNUAL GENERAL MEETING At the Annual General Meeting the following matters will be

Aker Solutions ASA: Fourth-Quarter Results 2018

February 8, 2019 - Aker Solutions increased the 2018 fourth quarter revenue to 7 billion, a rise of 8 percent compared to fourth quarter 2017, as the company won significant international awards in a competitive, but improving market. 4Q 2018 Financial Highlights · Revenue NOK 7 billion · EBITDA NOK 483 million · EBITDA margin 7.0% · EBITDA ex. special items NOK 495 million · EBITDA margin ex. special items 7.1% · Earnings per share ex. special items NOK 0.63 · Order intake NOK 5.3 billion · Order backlog NOK 35.1 billion With a strong execution on projects

Digia Plc’s Financial Statement Bulletin 2018

Digia PlcFinancial Statement Bulletin8 February 2019 at 8:00 am   Digia Plc’s Financial Statement Bulletin 2018 Net sales for the year increased 18.6%, and the operating profit improved substantially, to EUR 6.5 million. Unless otherwise stated, the comparison figures provided in parentheses always refer to the corresponding period of the previous year. October-December · Net sales EUR 31.2 (27.4) million, up 13.6 per cent · Operating profit EUR 1.4 (1.2) million, 4.6 (4.3) per cent of net sales · Earnings per share EUR 0.04 (0.03) January-December ·

There are no items matching the current filter
There are no more items matching the current filter
Back to top